Comparing a new targeted therapy to standard chemo for Waldenström macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study compares a new investigational drug called iopofosine I 131 with a standard combination chemotherapy (R-CD) for patients with Waldenström macroglobulinemia that has progressed after prior treatments, including a BTK inhibitor. The goal is to see which approach is more effective in controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Waldenström macroglobulinemia (a rare blood cancer).
- You must have had at least one prior treatment for your disease.
- You must have already tried a BTK inhibitor (a type of targeted therapy).
- Your disease must be progressing and need treatment (for example, rising IgM levels or new symptoms).
- You must be 18 or older and have a life expectancy of at least 6 months.
- You must have adequate kidney, liver, and blood cell counts, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Hear when a new Waldenstrom Macroglobulinaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.